Uwe Reuter, MD, PhD, MBA, Charité – University Medicine Berlin, Berlin, Germany, discusses the results from the open-label extension of the REGAIN study (NCT02614261) of galcanezumab in patients with chronic migraine. Patients with chronic migraine who completed the 3-month double-blind period of REGAIN entered a 9-month open-label extension. The study results showed that galcanezumab was effective and well-tolerated for up to 12 months of treatment. Galcanezumab treatment significantly reduced monthly migraine days, improved quality of life, and reduced acute medication intake. In the future, head-to-head comparison trials of gepants versus monoclonal antibodies targeting CGRP are needed to determine the differences between the two drug groups. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.